Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.2% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price was down 3.2% during mid-day trading on Thursday . The stock traded as low as $12.96 and last traded at $12.98. Approximately 93,077 shares traded hands during trading, a decline of 85% from the average daily volume of 607,855 shares. The stock had previously closed at $13.41.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating for the company.

Tonix Pharmaceuticals Price Performance

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $28.04 million, a PE ratio of 0.00 and a beta of 2.23. The company has a fifty day moving average price of $19.65 and a two-hundred day moving average price of $20.20.

Institutional Trading of Tonix Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP purchased a new stake in shares of Tonix Pharmaceuticals in the 4th quarter valued at about $66,000. Point72 Asset Management L.P. purchased a new stake in Tonix Pharmaceuticals during the 4th quarter valued at approximately $526,000. Jane Street Group LLC raised its stake in Tonix Pharmaceuticals by 5,932.3% during the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after acquiring an additional 1,635,119 shares during the last quarter. Northern Trust Corp purchased a new stake in Tonix Pharmaceuticals during the 4th quarter valued at approximately $162,000. Finally, Geode Capital Management LLC raised its stake in Tonix Pharmaceuticals by 1,600.1% during the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after acquiring an additional 1,855,907 shares during the last quarter. 82.26% of the stock is owned by hedge funds and other institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.